Liquid Biopsy Under PSMA Radioligand Therapy

Launched by WUERZBURG UNIVERSITY HOSPITAL · Aug 8, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new way to better understand and monitor advanced prostate cancer that no longer responds to standard hormone treatments. Specifically, it looks at a treatment called PSMA radioligand therapy (PSMA-RLT), which targets a protein found on prostate cancer cells. While this therapy can initially work well, the cancer often comes back quickly, and doctors don’t yet fully understand why. This study uses a “liquid biopsy,” which means taking blood samples before, during, and after treatment to look for tiny pieces of tumor DNA in the blood. This approach is easier and less invasive than traditional tissue biopsies and may help doctors predict how well the treatment will work, track changes in the cancer, and understand how the tumor develops resistance to the therapy.

Men with metastatic castration-resistant prostate cancer (meaning the cancer has spread and no longer responds to hormone-lowering treatments) who have already tried certain hormone and chemotherapy treatments may be eligible for this study. Participants will receive PSMA-RLT as part of their care and will provide blood samples at different times to help researchers gather important information. The study is currently recruiting patients at three hospitals in Germany, and those interested should be able to understand German or have a translator. Taking part means more frequent blood tests and sharing medical information, but it could help improve treatment for future patients with this form of prostate cancer.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Patients with mCRPC eligble for PSMA RLT
• • In-lable use for PSMA RLT
• • PSMA PET/CT not older than 8 weeks prior to first cycle of PSMA RLT
• • One previous line of antiandrogen receptor pathway treatment and one previous line of taxan based therapy
• • Age ≥ 18 years
• • Written informed consent
• • Sufficient knowledge of the German language or presence of a translator
• Exclusion Criteria:
• • Unwilling to adhere to study procedures
• • Missing interdisciplinary tumor conference advise for PSMA RLT